Why it matters

Jackson Laboratory’s new lobbying hire comes at a critical time. The nonprofit research institution faces mounting threats from animal welfare legislation and FDA policy shifts away from animal testing. This focus on external lobbying indicates a strategic adaptation at JAX during pivotal debates involving biomedical research.

By the numbers

JAX has spent $1.63 million on lobbying since 2003 across 65 filings. The organization conducted internal advocacy from 2017-2023, totaling $1.01 million. Twenty-First Century Group registered two senior lobbyists:

  • Jack Milton Fields Jr., with healthcare experience representing Sanofi Pasteur and Cardinal Health
  • Lisa D. Rulli, also with Cardinal Health and pharmaceutical lobbying background.

Broader Context

The FDA announced a major policy shift in April 2025 to phase out animal testing requirements. The Trump administration has proposed 40% budget cuts to NIH for 2026. Meanwhile, CRISPR gene editing and AI-based computational models are reducing reliance on traditional animal research methods.

The Agenda

JAX is lobbying on medical and disease research issues. The organization has historically focused on NIH and NSF funding, biomedical research infrastructure, and defending animal model use. Specific legislative priorities aren’t detailed in the registration.

Competitive Landscape

No information about competing lobbying efforts by other research institutions was available in the provided materials.

Between The Lines

H.Res.601 calls for doubling biomedical research investments over the next decade. But multiple bills threaten JAX’s research model, including the HEARTS Act requiring alternatives evaluation and the SPARE Act prohibiting animal use in federally funded research. These measures could fundamentally impact JAX’s role as a major laboratory mouse supplier.

The Bottom Line

Jackson Laboratory is adapting its advocacy strategy amid regulatory uncertainty. The timing suggests recognition that current policy debates could reshape biomedical research and its business model.

Spot something wrong? Report an issue with this article